Featured Publications
PD-1H (VISTA) expression in cutaneous squamous cell carcinoma is correlated with T cell infiltration and activation
Kidacki M, Cho C, Lopez-Giraldez F, Huang B, He J, Gaule P, Chen L, Vesely M. PD-1H (VISTA) expression in cutaneous squamous cell carcinoma is correlated with T cell infiltration and activation. Journal Of Investigative Dermatology 2025 PMID: 39983979, DOI: 10.1016/j.jid.2025.01.030.Peer-Reviewed Original ResearchCutaneous squamous cell carcinomaPD-L1 expressionT cell infiltrationPD-L1Squamous cell carcinomaVISTA expressionPD-1HCell carcinomaT cellsBlockade of PD-1Proliferation marker Ki-67Multiplexed quantitative immunofluorescencePD-L1 coexpressionTreatment of cutaneous squamous cell carcinomaControl T cellsPreclinical cancer studiesMyeloid cell functionImmunosuppressive microenvironmentPD-1Receptor antagonismKi-67Individual tumorsGranzyme B.Clinical trialsCancer clinical trialsImmune Checkpoint Agonists for Inflammatory Skin Diseases
Vesely M, Lizzul P, Klekotka P, Joller N, Raff A. Immune Checkpoint Agonists for Inflammatory Skin Diseases. Journal Of Investigative Dermatology 2025 PMID: 39927905, DOI: 10.1016/j.jid.2025.01.008.Peer-Reviewed Original ResearchSpatial Transcriptomics in Inflammatory Skin Diseases Using GeoMx Digital Spatial Profiling: A Practical Guide for Applications in Dermatology
Cho C, Haddadi N, Kidacki M, Woodard G, Shakiba S, Yıldız-Altay Ü, Richmond J, Vesely M. Spatial Transcriptomics in Inflammatory Skin Diseases Using GeoMx Digital Spatial Profiling: A Practical Guide for Applications in Dermatology. JID Innovations 2024, 5: 100317. PMID: 39559817, PMCID: PMC11570843, DOI: 10.1016/j.xjidi.2024.100317.Peer-Reviewed Original ResearchDigital spatial profilingInflammatory skin diseaseGeoMx Digital Spatial ProfilerSkin diseasesDiscoid lupus erythematosusNanoString GeoMx Digital Spatial ProfilingImmune milieuImmune microenvironmentLichen planusLupus erythematosusSingle cell RNA sequencingAberrant inflammationCell RNA sequencingSkin disease pathogenesisDisease pathogenesisManufacturer's guidelinesIndicators of diseaseDiseaseSpatial transcriptomics platformSkinTissue processingImmune Inhibitory Molecule PD-1 Homolog (VISTA) Colocalizes with CD11b Myeloid Cells in Melanoma and Is Associated with Poor Outcomes
Vesely M, Kidacki M, Gaule P, Gupta S, Chan N, Han X, Yeung J, Chen L. Immune Inhibitory Molecule PD-1 Homolog (VISTA) Colocalizes with CD11b Myeloid Cells in Melanoma and Is Associated with Poor Outcomes. Journal Of Investigative Dermatology 2023, 144: 106-115.e4. PMID: 37562584, DOI: 10.1016/j.jid.2023.07.008.Peer-Reviewed Original ResearchConceptsCD11b myeloid cellsImmune inhibitory moleculesPD-L1 expressionVISTA expressionMyeloid cellsFuture potential therapeutic targetsPD-L1/B7Tumor microenvironmentInhibitory moleculesMultiplexed quantitative immunofluorescencePrimary cutaneous melanomaImmunosuppressive tumor microenvironmentNegative prognostic biomarkerCurrent clinical trialsPotential therapeutic targetCause mortalityCritical cell typesPD-L1Poor outcomeTreatment of cancerMelanoma recurrenceCutaneous melanomaClinical trialsPrognostic biomarkerT cellsResistance Mechanisms to Anti-PD Cancer Immunotherapy
Vesely MD, Zhang T, Chen L. Resistance Mechanisms to Anti-PD Cancer Immunotherapy. Annual Review Of Immunology 2022, 40: 45-74. PMID: 35471840, DOI: 10.1146/annurev-immunol-070621-030155.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsAnti-PD therapyCancer immunotherapyMechanisms of resistanceImmune inhibitory moleculesFraction of patientsResistance mechanismsNormalization cancer immunotherapyAdditional immunotherapyPD-1Clinical evidenceAntigen presentationT cellsSolid tumorsTherapy resistanceH1 pathwayTumor microenvironmentImmunotherapyInhibitory moleculesHematopoietic malignanciesCancer treatmentTherapyPatientsCurrent studyCancer dataMalignancyPD-1H (VISTA)–mediated suppression of autoimmunity in systemic and cutaneous lupus erythematosus
Han X, Vesely MD, Yang W, Sanmamed MF, Badri T, Alawa J, López-Giráldez F, Gaule P, Lee SW, Zhang JP, Nie X, Nassar A, Boto A, Flies DB, Zheng L, Kim TK, Moeckel GW, McNiff JM, Chen L. PD-1H (VISTA)–mediated suppression of autoimmunity in systemic and cutaneous lupus erythematosus. Science Translational Medicine 2019, 11 PMID: 31826980, DOI: 10.1126/scitranslmed.aax1159.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsArthritisAutoantibodiesAutoimmunityDendritic CellsHumansInflammationInterferon Type ILupus Erythematosus, CutaneousLupus Erythematosus, SystemicMembrane ProteinsMice, Inbred BALB CMice, Inbred MRL lprMyeloid CellsNeutrophilsReceptors, Antigen, T-CellSignal TransductionTerpenesUp-RegulationConceptsPlasmacytoid dendritic cellsDiscoid lupus erythematosusSystemic lupus erythematosusCutaneous lupus lesionsPD-1HLupus erythematosusLupus lesionsAutoimmune diseasesKO miceT cellsMyeloid cellsHuman systemic lupus erythematosusBALB/c backgroundCutaneous lupus erythematosusInappropriate immune responseProgression of lupusSystemic autoimmune diseaseImmune cell expansionSuppression of autoimmunityAgonistic monoclonal antibodyDeath-1 homologCutaneous lupusProinflammatory neutrophilsDendritic cellsDLE lesionsCutaneous Lupus Erythematosus: Current and Future Pathogenesis-Directed Therapies.
Little AJ, Vesely MD. Cutaneous Lupus Erythematosus: Current and Future Pathogenesis-Directed Therapies. The Yale Journal Of Biology And Medicine 2020, 93: 81-95. PMID: 32226339, PMCID: PMC7087060.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsCutaneous lupus erythematosusDevelopment of CLEDisease pathogenesisAdaptive immune componentsClinical trial landscapeUnmet medical needFuture therapeutic strategiesPromising clinical trialsFuture pathogenesisLupus erythematosusSignificant morbidityAutoimmune diseasesImmune cellsClinical trialsCurrent treatmentTrial landscapeImmune componentsTherapeutic strategiesDrug AdministrationMedical needDiseasePathogenesisEnvironmental triggersTherapyType ICancer Immunoediting in the Era of Immuno-oncology.
Gubin MM, Vesely MD. Cancer Immunoediting in the Era of Immuno-oncology. Clinical Cancer Research 2022, 28: 3917-3928. PMID: 35594163, PMCID: PMC9481657, DOI: 10.1158/1078-0432.ccr-21-1804.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsCancer immunoeditingImmune-tumor cell interactionsCancer immunotherapyAbsence of immunotherapyDurable clinical responsesT cell biologyCell interactionsImmunotherapy resistanceClinical responseImmunosuppressive microenvironmentTumor immunogenicityImmuno-oncologyClinical dataPreclinical modelsImmunoeditingImmunotherapyHuman patientsImmune systemTumor microenvironmentCancerCancer progressionClinical subspecialtyImmunogenicityMicroenvironmentPatientsTreatment of cutaneous lupus with topical ruxolitinib cream
Park JJ, Little AJ, Vesely MD. Treatment of cutaneous lupus with topical ruxolitinib cream. JAAD Case Reports 2022, 28: 133-135. PMID: 36159722, PMCID: PMC9494033, DOI: 10.1016/j.jdcr.2022.08.038.Peer-Reviewed Case Reports and Technical NotesClinical and research updates on the VISTA immune checkpoint: immuno-oncology themes and highlights
Noelle R, Lines J, Lewis L, Martell R, Guillaudeux T, Lee S, Mahoney K, Vesely M, Boyd-Kirkup J, Nambiar D, Scott A. Clinical and research updates on the VISTA immune checkpoint: immuno-oncology themes and highlights. Frontiers In Oncology 2023, 13: 1225081. PMID: 37795437, PMCID: PMC10547146, DOI: 10.3389/fonc.2023.1225081.Commentaries, Editorials and LettersImmune checkpoint proteinsImmune checkpointsImmune systemT-lymphocyte antigen-4Cell death protein 1V-domain immunoglobulin suppressorDeath protein 1CD28 family membersAnti-VISTA antibodyT cell activationImportant homeostatic functionsVISTA blockadePD-1Proinflammatory changesImmune effectsMyeloid suppressionAntigen-4CTLA-4Immune cellsT cellsImmune responsePreclinical studiesClinical developmentHomeostatic functionsMyeloid lineageNormalization Cancer Immunotherapy for Melanoma
Vesely MD, Chen L. Normalization Cancer Immunotherapy for Melanoma. Journal Of Investigative Dermatology 2020, 140: 1134-1142. PMID: 32092349, PMCID: PMC7247948, DOI: 10.1016/j.jid.2020.02.005.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsNormalization cancer immunotherapyCancer immunotherapyImmune responseDysfunctional immune responseSystemic immune responsesContext of melanomaPatient survivalTreatment of cancerTumor responseImmunotherapyToxicity profileImmune systemTumor microenvironmentMelanomaCancerDistinct mechanismsResponseCliniciansSpatial characterization of interface dermatitis in cutaneous lupus reveals novel chemokine ligand-receptor pairs that drive disease.
Shakiba S, Haddadi NS, Afshari K, Lubov JE, Raef HS, Li R, Yildiz-Altay Ăś, Daga M, Refat MA, Kim E, de Laflin JG, Akabane A, Sherman S, MacDonald E, Strassner JP, Zhang L, Leon M, Baer CE, Dresser K, Liang Y, Whitley JB, Skopelja-Gardner S, Harris JE, Deng A, Vesely MD, Rashighi M, Richmond J. Spatial characterization of interface dermatitis in cutaneous lupus reveals novel chemokine ligand-receptor pairs that drive disease. BioRxiv 2024 PMID: 38260617, DOI: 10.1101/2024.01.05.574422.Peer-Reviewed Original Research
2025
Spatial transcriptomics reveals differential inflammatory pathways in discoid lupus erythematosus and lichen planus
Kidacki M, Cho C, Lopez-Giraldez F, Breidbart R, Jaiswal A, Lee M, Chowdhury S, Damsky W, Chen L, Vesely M. Spatial transcriptomics reveals differential inflammatory pathways in discoid lupus erythematosus and lichen planus. Journal Of Investigative Dermatology 2025 PMID: 40113031, DOI: 10.1016/j.jid.2025.02.148.Peer-Reviewed Original ResearchType 2 immunity to the rescue: enhancing antitumor immunity for skin cancer prevention
Vesely M, Christensen S. Type 2 immunity to the rescue: enhancing antitumor immunity for skin cancer prevention. Journal Of Clinical Investigation 2025, 135: e188018. PMID: 39744952, PMCID: PMC11684797, DOI: 10.1172/jci188018.Peer-Reviewed Original ResearchConceptsCutaneous squamous cell carcinomaThymic stromal lymphopoietinType 2 immunityActinic keratosisAK lesionsTh2 cellsPrevent cutaneous squamous cell carcinomaRecruitment of Th2 cellsCSCC preventionSquamous cell carcinomaMouse model of skin carcinogenesisModel of skin carcinogenesisDamage-associated molecular patternsKeratinocyte cell deathAntitumor immunityTopical calcipotriolSkin cancer preventionCell carcinomaPaired biopsiesPrecursor lesionsSkin carcinogenesisUnaffected skinMouse modelCancer preventionPremalignant keratinocytes
2024
Subcutaneous immunoglobulin-induced eczematous dermatitis.
Breidbart R, Vesely MD. Subcutaneous immunoglobulin-induced eczematous dermatitis. JAAD Case Rep 2024, 56: 60-62. PMID: 39866341, DOI: 10.1016/j.jdcr.2024.12.006.Peer-Reviewed Case Reports and Technical NotesMixed and undifferentiated autoimmune connective tissue diseases
Vesely M. Mixed and undifferentiated autoimmune connective tissue diseases. Clinics In Dermatology 2024 PMID: 39681290, DOI: 10.1016/j.clindermatol.2024.12.011.Peer-Reviewed Original ResearchConnective tissue diseaseTissue diseaseCutaneous manifestationsUndifferentiated connective tissue diseaseAutoimmune connective tissue diseaseEra of molecular diagnosticsSigns of systemic diseaseUrticarial vasculitisSystemic complicationsSjogren's syndromeClinical entityDescription of patientsSystemic diseaseClinical observationsDisease characterizationMolecular diagnosticsDiseasePatientsVasculitis207 Spatial transcriptomic profiling non-small cell lung cancer reveals potential drivers of CTL exclusion and dysfunction, and identifies novel predictive biomarkers for checkpoint blockade therapy
Cho C, Lopez-Giraldez F, Huang B, He J, Woodard G, Badri T, Kidacki M, Vesely M, Wang G, Ofori-Ntiamoah G, Ng E, Chen L. 207 Spatial transcriptomic profiling non-small cell lung cancer reveals potential drivers of CTL exclusion and dysfunction, and identifies novel predictive biomarkers for checkpoint blockade therapy. 2024, a236-a236. DOI: 10.1136/jitc-2024-sitc2024.0207.Peer-Reviewed Original ResearchIntravenous immunoglobulin-induced eczematous dermatitis treated with dupilumab
Singh K, Breidbart R, Jaiswal A, Damsky W, Choate K, Vesely M. Intravenous immunoglobulin-induced eczematous dermatitis treated with dupilumab. JAAD Case Reports 2024, 49: 102-105. PMID: 38952857, PMCID: PMC11214983, DOI: 10.1016/j.jdcr.2024.05.002.Peer-Reviewed Case Reports and Technical NotesUp-regulated PLA2G10 in cancer impairs T cell infiltration to dampen immunity
Zhang T, Yu W, Cheng X, Yeung J, Ahumada V, Norris P, Pearson M, Yang X, van Deursen W, Halcovich C, Nassar A, Vesely M, Zhang Y, Zhang J, Ji L, Flies D, Liu L, Langermann S, LaRochelle W, Humphrey R, Zhao D, Zhang Q, Zhang J, Gu R, Schalper K, Sanmamed M, Chen L. Up-regulated PLA2G10 in cancer impairs T cell infiltration to dampen immunity. Science Immunology 2024, 9: eadh2334. PMID: 38669316, DOI: 10.1126/sciimmunol.adh2334.Peer-Reviewed Original ResearchConceptsT cell infiltrationT cell exclusionT cellsResistance to anti-PD-1 immunotherapyPoor T-cell infiltrationAnti-PD-1 immunotherapyImmunogenic mouse tumorsT cell mobilizationHuman cancer tissuesTherapeutic immunotherapyCancer immunotherapyMouse tumorsChemokine systemImmunotherapyTumor tissuesImpaired infiltrationTumorLipid metabolitesHuman cancersCancer tissuesInfiltrationA2 groupCancerPLA2G10Up-regulatedAssociation of lichen planus with asthma and allergic rhinitis in the All of Us Research Program: a cross-sectional study
Richmond R, Murphy M, Edemobi P, Vesely M, Cohen J. Association of lichen planus with asthma and allergic rhinitis in the All of Us Research Program: a cross-sectional study. Clinical And Experimental Dermatology 2024, 49: 1067-1069. PMID: 38589773, PMCID: PMC11340807, DOI: 10.1093/ced/llae101.Peer-Reviewed Original Research
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply